Navigation Links
OncoSec Medical Closes $1.1M Financing
Date:3/31/2011

SAN DIEGO, March 31, 2011 /PRNewswire/ -- OncoSec Medical Inc. (OTC BB: ONCS), a developer of innovative medical approaches to treat solid tumor cancers, announced today that it has raised more than $1 million of new capital through the issuance of units to three institutional investors. OncoSec issued 1,456,000 units at a price of $0.75 per unit for gross proceeds of $1,092,000. Each unit consisted of one share of common stock and one share purchase warrant entitling the warrant holder to purchase an additional share of common stock at a price of $1.00 per share for a period of five years from closing. These shares, and shares underlying the warrants, were issued in a private placement under Regulation S and/or Section 4(2) of the Securities Act of 1933, as amended, and are restricted securities under such Act.

(Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

OncoSec intends to use proceeds from the financing to acquire intellectual property from Inovio Pharmaceuticals, Inc., to advance its clinical development pipeline, and for working capital purposes.

About OncoSec Medical Inc.

OncoSec (OTC BB: ONCS) designs, develops and commercializes innovative medical approaches to treat solid tumor cancers for which currently approved therapies are inadequate based on their efficacy level or side effect profile. The company's therapies are based on the use of electroporation delivery in combination with an approved cancer drug or a gene-based cytokine. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Globus Medical Raises $110 Million in Series E Financing Round
8. Quark Pharmaceuticals Appoints New Chief Medical Officer
9. Boston University Biomedical Engineers Find Chink in Bacterias Armor
10. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
11. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... MINNEAPOLIS , Feb. 10, 2016 Urologix, ... for the treatment of Benign Prostatic Hyperplasia (BPH), announces ... Ash Keswani , a medical device industry veteran ... of the Limited Liability Company.  ... and service lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, ...
(Date:2/10/2016)... Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko ... completed, through its indirect wholly-owned subsidiary Laurel Acquisition Inc. ... outstanding shares of common stock of Ocata Therapeutics, Inc. ... "Ocata") for a price of US$8.50 per share net ... the Tender Offer on November 19, 2015, U.S. Eastern ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in partnership ... Grand Challenge to generate a biomarker to track TDP43 aggregation. ... up to a $1 million investment. ... disease that affects nerve cells in the brain and the ... initiate and control muscle movement, which often leads to total ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel ... the Food Bank of Eastern Michigan last Friday in order to aid in the ... the Midwest to include a facility located in Clio, only 15 miles away from ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting ... Healthcare, recently partnered with Heart City Health Center to improve access ... years, Heart City Health Center has provided the Elkhart community with access to ...
(Date:2/10/2016)... , ... February 10, 2016 , ... 10 Best ... There were three leading bottled water brand owners that topped the list as a ... connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch water ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors ... the latest addition to its growing list of Partner Firms. S.S. Nesbitt ... from Orlando to Huntsville and in between. , Harnessing the experience and insights ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):